Results 111 to 120 of about 287,802 (318)

Polycythemia vera treatment algorithm 2018

Blood Cancer Journal, 2018
Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old.
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib

Cancer, Volume 131, Issue 17, 1 September 2025.
Abstract Background The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients. Methods To further explore this, the authors performed a subanalysis of the “RUX‐MF” study (NCT06516406) with ...
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, Elena M. Elli, Erika Morsia, Mirko Farina, Mario Tiribelli, Giulia Benevolo, Eloise Beggiato, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandro Isidori, Alessandra Dedola, Emilia Scalzulli, Andrea Duminuco, Luca Tosoni, Alda Strazimiri, Roberto M. Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Chiara Sartor, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall   +31 more
wiley   +1 more source

Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms [PDF]

, 2013
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2V617F mutations.
Bianchini, Michele, de Brasi, Carlos Daniel, Gargallo, Patricia Martha, Gonzalez, Mariana Selena, Larripa, Irene Beatriz, Stanganelli, Carmen Graciela, Zalcberg, Ilana   +6 more
core   +3 more sources

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Seminars in Immunopathology, 2018
The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in ...
H. Hasselbalch, M. Holmström
semanticscholar   +1 more source

Venesection and resolution of erythrocytosis are not associated with reduced thrombotic risk in secondary and idiopathic polycythaemia: Results from a dual centre, 5‐year retrospective study

British Journal of Haematology, EarlyView.
B. D. Maybury, E. Jongman, C. Morgan, K. Sheikh, J. Prasangika, M. Asif, M. Bisp, C. Lam, F. Noor, S. A. Y. Abbas, H. Dhunya, R. Lloyd, M. H. A. Chowdhury, P. Rathnayake, M. Aquil, W. Butterfield, T. Jha, P. Dyer, R. J. Buka, P. L. R. Nicolson, HaemSTAR Collaborators, Zoha Mansoor, Farhan Patel, Sanober Sanober, Rahul Ghandi, Eman Hassan   +25 more
wiley   +1 more source

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

HemaSphere, Volume 9, Issue 9, September 2025.
Abstract Accelerated‐phase (AP) or blast‐phase (BP) myeloproliferative neoplasms (MPNs) are associated with dismal prognosis, with non‐curative therapies such as hypomethylating agents (HMAs) considered in patients not eligible for intensive therapy, while some studies advocate for combination therapy with either ruxolitinib (RUXO) or venetoclax (VEN).
Corentin Orvain, Suzanne Tavitian, Clémence Mediavilla, Françoise Boyer, Alberto Santagostino, Geoffroy Venton, Samia Madene, Tony Marchand, Pascal Turlure, Diane Lara, Lenaig Le Clech, Katell Le Du, Jean‐Baptiste Robin, Lise Willems, Anaïse Blouet, Thomas Systchenko, Mathieu Wemeau, Hélène Pasquer, Mélanie Mercier, Christophe Nicol, Laurence Legros, Antoine Machet, Franck‐Emmanuel Nicolini, Lydia Roy, Clémentine Salvado, Guillaume Denis, Elsa Lestang, Kamel Laribi, Damien Luque Paz, Jean‐Jacques Kiladjian, Eric Lippert, Lina Benajiba, Jean‐Christophe Ianotto   +32 more
wiley   +1 more source

Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature

Annals of Saudi Medicine, 2016
Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz, Sinan Kulakoglu, Hasan Gorkem, Bilal Aygun, Ali Cetinkaya   +4 more
doaj   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, Volume 19, Issue 8, Page 2174-2195, August 2025.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet, Bennett, Cavan, Dovey, Oliver M, Ghevaert, Cedric, Gonzalez-Arias, Carlos, Green, Anthony R, Grinfeld, Jacob, Hamilton, Tina L, Kent, David G, Klampfl, Thorsten, Li, Juan, Loughran, Stephen, Park, Hyun Jung, Pask, Dean C, Prins, Daniel, Sneade, Rachel, Vassiliou, George S, Williams, Matthew   +17 more
core   +1 more source

Updates in the management of polycythemia vera and essential thrombocythemia

Therapeutic Advances in Hematology, 2019
Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar   +1 more source